Haemonetics Corporation
HAE
$56.66
-$1.80-3.08%
NYSE
| 12/27/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.75% | -5.27% | -4.40% | -3.70% | 3.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.75% | -5.27% | -4.40% | -3.70% | 3.66% |
| Cost of Revenue | -10.09% | -14.00% | -17.43% | -14.84% | 0.43% |
| Gross Profit | 2.93% | 1.78% | 7.01% | 5.41% | 6.30% |
| SG&A Expenses | 0.17% | -4.70% | -1.41% | 1.36% | -0.36% |
| Depreciation & Amortization | -10.61% | -8.82% | -8.65% | 8.35% | 76.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.30% | -9.53% | -10.08% | -6.86% | 3.06% |
| Operating Income | 13.42% | 15.12% | 27.38% | 15.10% | 6.43% |
| Income Before Tax | 20.15% | 14.72% | -3.31% | 202.11% | 13.37% |
| Income Tax Expenses | 22.64% | 15.89% | 33.55% | 318.64% | -2.85% |
| Earnings from Continuing Operations | 19.33% | 14.34% | -11.32% | 184.68% | 20.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.33% | 14.34% | -11.32% | 184.68% | 20.02% |
| EBIT | 13.42% | 15.12% | 27.38% | 15.10% | 6.43% |
| EBITDA | 7.39% | 9.08% | 16.95% | 14.51% | 11.26% |
| EPS Basic | 28.23% | 22.30% | -6.11% | 193.92% | 21.16% |
| Normalized Basic EPS | 27.73% | 24.83% | 2.77% | 5.16% | -5.01% |
| EPS Diluted | 28.38% | 22.73% | -5.41% | 194.65% | 21.31% |
| Normalized Diluted EPS | 28.09% | 25.48% | 3.52% | 5.83% | -4.40% |
| Average Basic Shares Outstanding | -6.95% | -6.50% | -5.56% | -3.14% | -0.95% |
| Average Diluted Shares Outstanding | -7.21% | -6.98% | -6.23% | -3.76% | -1.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |